Isotyping immunoglobulins using accurate molecular mass

Patent metadata

Field	Value
Publication number	US-11604196-B2
Application number	US-202016930790-A
Country	US
Kind code	B2
Filing date	Jul 16, 2020
Priority date	Apr 4, 2014
Publication date	Mar 14, 2023
Grant date	Mar 14, 2023

Abstract

This document relates to methods for detecting and quantifying heavy and light chains of immunoglobulin using mass spectrometry techniques.

First claim

What is claimed is:

1. A method for detecting the total amount of immunoglobulin light chains in a sample, the method comprising:
a) providing a biological sample comprising immunoglobulins, paired immunoglobulin heavy and light chains, or mixtures thereof;
b) immunopurifying the sample, wherein the immunopurifying comprises using an antibody selected from the group consisting of an anti-human IgG antibody, an anti-human IgA antibody, an anti-human IgM antibody, an anti-human IgD antibody, an anti-human IgE antibody, and combinations thereof;
c) subjecting the immunopurified sample to a decoupling step wherein immunoglobulin light chains are decoupled from immunoglobulin heavy chains;
d) subjecting the decoupled sample to a mass spectrometry technique to obtain a mass spectrum of the sample, said mass spectrum comprising one or more peaks corresponding to one or more intact immunoglobulin kappa and lambda light chains in the sample; wherein said one or more peaks quantify the total amount of the one or more intact immunoglobulin light chains in the sample; and
e) comparing the total amount of the one or more intact immunoglobulin kappa and lambda light chains in the sample to a reference value.

2. The method of claim 1 , wherein a higher than reference total amount indicates that the subject has polyclonal hyperglobulinemia.

3. The method of claim 1 wherein the total amount of the intact immunoglobulin kappa and lambda light chains in the sample is at least 2-fold higher than the reference value.

4. The method of claim 1 , further comprising determining the ratio of kappa and lambda immunoglobulin light chains in the sample after step c).

5. The method of claim 1 , wherein the immunopurifying further comprises using an antibody selected from the group consisting of an anti-human kappa antibody, an anti-human lambda antibody, and combinations thereof.

6. The method of claim 1 , wherein the antibody is a non-human antibody.

7. The method of claim 6 , wherein the non-human antibody is at least one of a camelid antibody, a cartilaginous fish antibody, llama, sheep, goat, or a mouse antibody.

8. The method of claim 7 , wherein the antibody is a single domain antibody fragment.

9. The method of claim 8 , wherein the single domain antibody fragment is derived from a camelid antibody, a cartilaginous fish antibody, llama, a mouse antibody, sheep, goat, or a human antibody.

10. The method of claim 9 , wherein the single domain antibody fragment is selected such that the mass spectrum generated in step c) for the single domain antibody fragment does not overlap with the mass spectrum generated in step c) for the immunoglobulin light chain or immunoglobulin heavy chain.

11. The method of claim 10 , wherein the single domain antibody fragment is selected such that the single domain antibody fragment generates a signal of about 12,500 to about 15,000 m/z in step c) with a single charge.

12. The method of claim 1 , wherein the sample comprising immunoglobulin light chains, immunoglobulin heavy chains, or mixtures thereof is analyzed as a single fraction in a single analysis.

13. The method of claim 1 , further comprising determining the pairing of immunoglobulin heavy chains and immunoglobulin light chains in the sample.

14. The method of claim 1 , further comprising isotyping one or more of the immunoglobulin light chains in the sample.

15. The method of claim 1 , further comprising isotyping one or more of the immunoglobulin heavy chains in the sample.

16. The method of claim 1 , further comprising isotyping one or more of the immunoglobulin light chains and immunoglobulin heavy chains in the sample.

17. The method of claim 1 , further comprising identifying one or more of the immunoglobulin light chains and immunoglobulin heavy chains.

18. A method for monitoring treatment of a hyperglobulinemia in a subject comprising detecting the total amount of immunoglobulin light chains in a sample, the method comprising:
a) providing a first biological sample from the subject before the treatment and a second sample during or after the treatment both samples comprising immunoglobulins, paired immunoglobulin heavy and light chains, or mixtures thereof;
b) immunopurifying each sample, wherein the immunopurifying comprises using an antibody selected from the group consisting of an anti-human IgG antibody, an anti-human IgA antibody, an anti-human IgM antibody, an anti-human IgD antibody, an anti-human IgE antibody, and combinations thereof;
c) subjecting each immunopurified sample to a decoupling step wherein immunoglobulin light chains are decoupled from immunoglobulin heavy chains;
d) subjecting each decoupled sample to a mass spectrometry technique to obtain a mass spectrum of the sample, said mass spectrum comprising one or more peaks corresponding to one or more intact immunoglobulin kappa and lambda light chains in the sample; wherein said one or more peaks quantify the total amount of the one or more intact immunoglobulin light chains in the sample; and
e) comparing the total amount of the one or more intact immunoglobulin kappa and lambda light chains in the second sample to the total amount of the one or more intact immunoglobulin kappa and lambda light chains in the first sample.

Assignees

• Mayo Found Medical Education & Res

Inventors

• Murray David L
• Barnidge David R
• Dasari Surendra
• Mills John R

Classifications

• G01N33/6848 Primary

  Methods of protein analysis involving mass spectrometry · CPC title

• G01N2800/52

  Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis · CPC title

• G01N30/7266

  by electric field, e.g. electrospray · CPC title

• G01N33/6857

  Antibody fragments · CPC title

• G01N2800/7095

  Inflammation · CPC title